The Radiation Therapy Oncology Group (RTOG) has committed itself as a Research Base for the Community Clinical Oncology Program (CCOP). This application documents the current RTOG cancer control organization within which the CCOP members participate in the areas of cancer treatment studies and cancer prevention and control scientific proposals. The RTOG, with its experience and expertise in local-regional cancer treatment and control, will continue to utilize the CCOP network as one of the major components of its cancer control research program, which focuses on intervention studies in the cured and potentially curable cancer patient. This application documents the Cancer Prevention and Control (CPC) activity within the RTOG over the past two years, including completed and current intervention studies for head and neck, and skin, as well as studies addressing symptom control and chemoprevention. In addition, this proposal documents she participation of CCOP members in RTOG treatment and Cancer Control studies, as well as the involvement of RTOG members in Cancer Control studies. This proposal divides the proposed cancer control activities into four sections -intervention, late effect normal tissue (LENT), chemoprevention and complementary and alternative medicine (CAM). The interventional studies will continue to dominate the CPC activities; the LENT program will study the role of cytokine dysfunction in predicting late effects; the chemoprevention program will address the potential of surrogate markers in evaluating chemopreventive agents; and the complementary alternative medicine program will provide studies to validate whether current agents can be utilized as interventional agents. The growth of each program will provide additional opportunities for CCOP members to participate in RTOG research activities and present the RTOG member with an experienced and enthusiastic group of community radiation oncologists. The administrative functions will include the Vice-Chair for Cancer Control, as well as the Chairs for each section. A Steering committee composed of Chairs of the QOL, Economic Impact, Special Population, and CCOP representation of the disease site committees will evaluate and set priorities. The Membership committee evaluates each CCOP to assure adherence to all NCI requirements. The Administrative, Protocol, Quality Assurance and Data Management Units of RTOG are utilized in initiating these cancer control trials, and the quality assurance procedures, including on-site audits, are applied to the community network. The goal is for the continued integration of the CCOPs into the RTOG to insure all members the opportunity to participate in all facets of RTOG activities in order to facilitate the transference of the latest scientific information into the community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037422-16
Application #
6604948
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J1))
Program Officer
O'Mara, Ann M
Project Start
1994-06-01
Project End
2005-05-31
Budget Start
2003-06-01
Budget End
2004-05-31
Support Year
16
Fiscal Year
2003
Total Cost
$914,646
Indirect Cost
Name
American College of Radiology
Department
Type
DUNS #
062485800
City
Reston
State
VA
Country
United States
Zip Code
20191
Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47
Lawrence, Yaacov R; Moughan, Jennifer; Magliocco, Anthony M et al. (2018) Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer 124:491-498
Raman, Srinivas; Ding, Keyue; Chow, Edward et al. (2018) Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases. Qual Life Res 27:1089-1098
Dormer, James D; Halicek, Martin; Ma, Ling et al. (2018) Convolutional Neural Networks for the Detection of Diseased Hearts Using CT Images and Left Atrium Patches. Proc SPIE Int Soc Opt Eng 10575:
Dormer, James D; Ma, Ling; Halicek, Martin et al. (2018) Heart Chamber Segmentation from CT Using Convolutional Neural Networks. Proc SPIE Int Soc Opt Eng 10578:
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
Seider, Michael J; Pugh, Stephanie L; Langer, Corey et al. (2018) Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Ann Nucl Med 32:553-560
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Regine, William F; Winter, Kathryn; Abrams, Ross A et al. (2018) Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol 3:154-162
Konski, Andre; Bhargavan, Mytheryi; Owen, Jean et al. (2018) An Economic Analysis of Radiation Therapy Oncology Group 94-10: Cost-Efficacy of Concurrent vs. Sequential Chemoradiotherapy. J Radiat Oncol 7:195-201

Showing the most recent 10 out of 326 publications